For women with primary progressive MS, could bestselling drug be doing more harm than good?
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a form of MS thought to ...
Apr 15, 2026
0
4









